New Treatment Now Available for Canadians with Metastatic Non-Small Cell Lung Cancer
KIRKLAND, QC, April 20, 2016 /CNW Telbec/ - Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that KEYTRUDA® (pembrolizumab) received conditional approval for the treatment of Canadians living with metastatic...
Read More